Safety and efficacy of GST-HG141, a novel HBV capsid assembly modulator, for the treatment of chronic hepatitis B patients with low-level viremia: a randomized, double-blind, placebo-controlled, multicenter phase II studyChong Wang, Junqi Niu, Guicheng Wu et al.|EClinicalMedicine|2025Cited by 7
Efficacy and safety of GLS4 with entecavir vs entecavir alone in chronic hepatitis B patients: A multicenter clinical trialMingyuan Zhang, Junqi Niu, Yanhang Gao et al.|Journal of Infection|2025Cited by 6
LBP-014 HBsAg loss and seroconversion after 16-week or 24-week AHB-137 treatment in HBeAg-negative chronic hepatitis B participants on NA therapy: results from an ongoing multicenter, randomized phase IIb studyYanhang Gao, Junqi Niu, Xieer Liang et al.|Journal of Hepatology|2025Cited by 2
THU-240 30% of inactive HBsAg carriers achieved clinical cure at 48 weeks with Pegylated Interferon alpha-2b therapy: a multicenter real- world study (STARHB Project in China)- 2.5 years data updateShan Ren, Xinyue Chen, Jing Zhao et al.|Journal of Hepatology|2025Cited by 0